Drug Type Small molecule drug |
Synonyms Brilanestrant (USAN/INN), ARN 810, ARN-810 + [4] |
Target |
Mechanism ERα antagonists(Estrogen receptor alpha antagonists) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H20ClFN2O2 |
InChIKeyBURHGPHDEVGCEZ-KJGLQBJMSA-N |
CAS Registry1365888-06-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11264 | Brilanestrant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 2 | US | 04 Dec 2015 | |
Advanced breast cancer | Phase 2 | AU | 04 Dec 2015 | |
Advanced breast cancer | Phase 2 | DE | 04 Dec 2015 | |
Advanced breast cancer | Phase 2 | KR | 04 Dec 2015 | |
Advanced breast cancer | Phase 2 | ES | 04 Dec 2015 | |
Advanced breast cancer | Phase 2 | GB | 04 Dec 2015 | |
Metastatic breast cancer | Phase 2 | US | 04 Dec 2015 | |
Metastatic breast cancer | Phase 2 | AU | 04 Dec 2015 | |
Metastatic breast cancer | Phase 2 | DE | 04 Dec 2015 | |
Metastatic breast cancer | Phase 2 | KR | 04 Dec 2015 |
Phase 2 | 71 | (GDC-0810) | hfumnlnphb(nfqkhdziiq) = ishvfjvvul yxovonyoko (iomiqnxgfm, icyjxngeft - dqjgngcfgp) View more | - | 23 Apr 2021 | ||
(Fulvestrant) | hfumnlnphb(nfqkhdziiq) = rkdoqchswr yxovonyoko (iomiqnxgfm, nljyasaxcq - tonoynouvl) View more | ||||||
Phase 1 | 41 | bacqcfapkw(nlvnerphcj) = 600 mg QD given with food zbonlufdof (ofbkmliywd ) View more | Positive | 01 Aug 2015 |